The term monoclonal gammopathy of clinical significance (MGCS) refers to a group of symptomatic monoclonal gammopathies that do not meet the diagnostic criteria for malignant plasma cell disorders, such as multiple myeloma or Waldenström macroglobulinemia. These symptoms are attributable to the paraneoplastic effects of monoclonal immunoglobulins that occur through diverse mechanisms. The presence of symptoms distinguishes MGCS from monoclonal gammopathy of undetermined significance, which lacks significant symptomatic presentation. The presentations of MGCS are manifold, adding to the diagnostic challenge. Clinical suspicion is key for accurate and timely diagnosis. Radiologic imaging can provide pivotal information to guide the diagnosis. In this review, we discuss MGCS from a radiology perspective and highlight pertinent imaging features associated with the disorders.
Objective. To assess the accuracy and stability of areal bone-mineral-density (aBMD) measurements from multi-energy CT localizer radiographs acquired using photon-counting detector (PCD) CT. Approach. A European Spine Phantom (ESP) with hydroxyapatite (HA 0.5, 1.0 and 1.5 g cm−2) was scanned using clinical PCD-CT and a dual-energy x-ray absorptiometry (DXA) to compare aBMD values. To assess aBMD stability and reproducibility, PCD-localizers were acquired twice a day for one week, and once per week for five weeks. Multiple ESP anteroposterior thicknesses (18, 26, 34, and 40 cm) were achieved using a synthetic gel layer and scanned across eight tube current values for both 120 kV (15–120 mA) and 140 kV (10–80 mA). One-way analysis of variance was performed for statistical significance (p < 0.05 considered significant). Quantitative HA and water maps were reconstructed using a prototype material-decomposition software, and aBMD was calculated after background correction. In vivo performance of PCD-based aBMD was illustrated using a patient scan acquired at 140 kV and 40 mA, and lumbar aBMD values were compared with DXA. Main results. The ESP aBMD values from PCD-localizers demonstrated excellent day-to-day stability with a coefficient-of-variation ranging from 0.42% to 0.53%, with mean absolute percentage errors (MAPE) of less than 5% for all three vertebral bodies. The coefficient-of-variation for weekly scans ranged from 0.17% to 0.60%, again with MAPE below 5% for all three vertebral bodies. Across phantom sizes and tube currents, the MAPE values varied ranging from 1.84% to 13.78% for 120 kV, and 1.38%–9.11% for 140 kV. No significant difference was found between different tube currents. For the standard phantom size, DXA showed 11.21% MAPE whereas PCD-CT showed 3.04% MAPE. For the patient scan, deviation between PCD-based aBMD values and those obtained from DXA ranged from 0.07% to 9.82% for different lumbar vertebra. Significance. This study highlights the accuracy and stability of PCD-CT localizers for measuring aBMD. We demonstrated aBMD accuracy across different sizes and showed that higher radiation doses did not inherently increase aBMD accuracy.
17 June 2025 in Journal of the American Heart Association